Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment
Loading...
Date
Authors
Tsimihodimos, V.
Dounousi, E.
Siamopoulos, K. C.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Am J Nephrol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
BACKGROUND/AIMS: Cardiovascular disease (CVD) is a major cause of mortality in patients with mild to moderate chronic kidney disease (CKD) and end-stage renal disease (ESRD). Dyslipidemia has been established as a well-known traditional risk factor for CVD in the general population and it is well known that patients with CKD exhibit significant alterations in lipoprotein metabolism. In this review the pathogenesis and treatment of renal dyslipidemia are discussed. METHODS: Studies on lipid abnormalities in CKD stages 1-4, in nephrotic syndrome, and in hemodialysis and peritoneal dialysis patients are analyzed, as well as the lipid profile of kidney graft recipients. Also, the results of the effects of epoietin treatment and hypolipidemic drugs in CKD patients are reported. RESULTS: Disturbances in lipoprotein metabolism are evident even at the early stages of CKD and usually follow a downhill course that parallels the decline of renal function. However, several intrinsic or exogenous factors can influence the phenotypic expression of these alterations. According to the literature, current evidence suggests that unlike dialysis patients, mild to moderate CKD patients could be benefit from the use of statins. CONCLUSION: The use of statins is indicated in patients with mild to moderate CKD, while in subjects with ESRD lipid-lowering therapy should be individualized.
Description
Keywords
Dyslipidemias/*complications/*pathology/therapy, Erythropoietin/metabolism, Humans, Hypertriglyceridemia/metabolism, Kidney Failure, Chronic/*complications/*pathology/therapy, Kidney Transplantation/methods, Lipid Metabolism, Lipids/chemistry, Models, Biological, Nephrotic Syndrome/metabolism, Peritoneal Dialysis, Recombinant Proteins, Renal Dialysis, Treatment Outcome
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/18612199
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000144024&Ausgabe=239023&ProduktNr=223979&filename=000144024.pdf
http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000144024&Ausgabe=239023&ProduktNr=223979&filename=000144024.pdf
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής